193 related articles for article (PubMed ID: 20305694)
21. Artemin-stimulated progression of human non-small cell lung carcinoma is mediated by BCL2.
Tang JZ; Kong XJ; Kang J; Fielder GC; Steiner M; Perry JK; Wu ZS; Yin Z; Zhu T; Liu DX; Lobie PE
Mol Cancer Ther; 2010 Jun; 9(6):1697-708. PubMed ID: 20530713
[TBL] [Abstract][Full Text] [Related]
22. Estrogen responsiveness of IBEP-2, a new human cell line derived from breast carcinoma.
Journé F; Body JJ; Leclercq G; Nonclercq D; Laurent G
Breast Cancer Res Treat; 2004 Jul; 86(1):39-53. PubMed ID: 15218360
[TBL] [Abstract][Full Text] [Related]
23. ER-α variant ER-α36 mediates antiestrogen resistance in ER-positive breast cancer stem/progenitor cells.
Deng H; Yin L; Zhang XT; Liu LJ; Wang ML; Wang ZY
J Steroid Biochem Mol Biol; 2014 Oct; 144 Pt B():417-26. PubMed ID: 25158023
[TBL] [Abstract][Full Text] [Related]
24. Wilms' tumor 1 suppressor gene mediates antiestrogen resistance via down-regulation of estrogen receptor-alpha expression in breast cancer cells.
Han Y; Yang L; Suarez-Saiz F; San-Marina S; Cui J; Minden MD
Mol Cancer Res; 2008 Aug; 6(8):1347-55. PubMed ID: 18708366
[TBL] [Abstract][Full Text] [Related]
25. Estrogen induces death of tamoxifen-resistant MCF-7 cells: contrasting effect of the estrogen receptor downregulator fulvestrant.
Planas-Silva MD; Waltz PK; Kilker RL
J Steroid Biochem Mol Biol; 2006 Mar; 98(4-5):193-8. PubMed ID: 16464573
[TBL] [Abstract][Full Text] [Related]
26. Resistance to different antiestrogens is caused by different multi-factorial changes and is associated with reduced expression of IGF receptor Ialpha.
Brockdorff BL; Heiberg I; Lykkesfeldt AE
Endocr Relat Cancer; 2003 Dec; 10(4):579-90. PubMed ID: 14713268
[TBL] [Abstract][Full Text] [Related]
27. Hydroxychloroquine inhibits autophagy to potentiate antiestrogen responsiveness in ER+ breast cancer.
Cook KL; Wärri A; Soto-Pantoja DR; Clarke PA; Cruz MI; Zwart A; Clarke R
Clin Cancer Res; 2014 Jun; 20(12):3222-32. PubMed ID: 24928945
[TBL] [Abstract][Full Text] [Related]
28. Stabilization of MORC2 by estrogen and antiestrogens through GPER1- PRKACA-CMA pathway contributes to estrogen-induced proliferation and endocrine resistance of breast cancer cells.
Yang F; Xie HY; Yang LF; Zhang L; Zhang FL; Liu HY; Li DQ; Shao ZM
Autophagy; 2020 Jun; 16(6):1061-1076. PubMed ID: 32401166
[TBL] [Abstract][Full Text] [Related]
29. Breast Cancer Resistance to Antiestrogens Is Enhanced by Increased ER Degradation and ERBB2 Expression.
Shibata T; Watari K; Izumi H; Kawahara A; Hattori S; Fukumitsu C; Murakami Y; Takahashi R; Toh U; Ito KI; Ohdo S; Tanaka M; Kage M; Kuwano M; Ono M
Cancer Res; 2017 Jan; 77(2):545-556. PubMed ID: 27879270
[TBL] [Abstract][Full Text] [Related]
30. Tamoxifen-bound estrogen receptor (ER) strongly interacts with the nuclear matrix protein HET/SAF-B, a novel inhibitor of ER-mediated transactivation.
Oesterreich S; Zhang Q; Hopp T; Fuqua SA; Michaelis M; Zhao HH; Davie JR; Osborne CK; Lee AV
Mol Endocrinol; 2000 Mar; 14(3):369-81. PubMed ID: 10707955
[TBL] [Abstract][Full Text] [Related]
31. Sequential versus combined treatment of human breast cancer cells with antiestrogens and the vitamin D analogue EB1089 and evaluation of predictive markers for vitamin D treatment.
Christensen GL; Jepsen JS; Fog CK; Christensen IJ; Lykkesfeldt AE
Breast Cancer Res Treat; 2004 May; 85(1):53-63. PubMed ID: 15039597
[TBL] [Abstract][Full Text] [Related]
32. Artemin stimulates oncogenicity and invasiveness of human endometrial carcinoma cells.
Pandey V; Qian PX; Kang J; Perry JK; Mitchell MD; Yin Z; Wu ZS; Liu DX; Zhu T; Lobie PE
Endocrinology; 2010 Mar; 151(3):909-20. PubMed ID: 20118197
[TBL] [Abstract][Full Text] [Related]
33. The estrogen receptor influences microtubule-associated protein tau (MAPT) expression and the selective estrogen receptor inhibitor fulvestrant downregulates MAPT and increases the sensitivity to taxane in breast cancer cells.
Ikeda H; Taira N; Hara F; Fujita T; Yamamoto H; Soh J; Toyooka S; Nogami T; Shien T; Doihara H; Miyoshi S
Breast Cancer Res; 2010; 12(3):R43. PubMed ID: 20579400
[TBL] [Abstract][Full Text] [Related]
34. SHON is a novel estrogen-regulated oncogene in mammary carcinoma that predicts patient response to endocrine therapy.
Jung Y; Abdel-Fatah TM; Chan SY; Nolan CC; Green AR; Ellis IO; Li L; Huang B; Lu J; Xu B; Chen L; Ma RZ; Zhang M; Wang J; Wu Z; Zhu T; Perry JK; Lobie PE; Liu DX
Cancer Res; 2013 Dec; 73(23):6951-62. PubMed ID: 24296488
[TBL] [Abstract][Full Text] [Related]
35. The neuropeptide y y(1) receptor: a diagnostic marker? Expression in mcf-7 breast cancer cells is down-regulated by antiestrogens in vitro and in xenografts.
Memminger M; Keller M; Lopuch M; Pop N; Bernhardt G; von Angerer E; Buschauer A
PLoS One; 2012; 7(12):e51032. PubMed ID: 23236424
[TBL] [Abstract][Full Text] [Related]
36. Distinctive functions of p160 steroid receptor coactivators in proliferation of an estrogen-independent, tamoxifen-resistant breast cancer cell line.
Karmakar S; Foster EA; Blackmore JK; Smith CL
Endocr Relat Cancer; 2011 Feb; 18(1):113-27. PubMed ID: 21059860
[TBL] [Abstract][Full Text] [Related]
37. Circumventing tamoxifen resistance in breast cancers using antiestrogens that induce unique conformational changes in the estrogen receptor.
Connor CE; Norris JD; Broadwater G; Willson TM; Gottardis MM; Dewhirst MW; McDonnell DP
Cancer Res; 2001 Apr; 61(7):2917-22. PubMed ID: 11306468
[TBL] [Abstract][Full Text] [Related]
38. Characterization of BCAR4, a novel oncogene causing endocrine resistance in human breast cancer cells.
Godinho M; Meijer D; Setyono-Han B; Dorssers LC; van Agthoven T
J Cell Physiol; 2011 Jul; 226(7):1741-9. PubMed ID: 21506106
[TBL] [Abstract][Full Text] [Related]
39. LYN-activating mutations mediate antiestrogen resistance in estrogen receptor-positive breast cancer.
Schwarz LJ; Fox EM; Balko JM; Garrett JT; Kuba MG; Estrada MV; González-Angulo AM; Mills GB; Red-Brewer M; Mayer IA; Abramson V; Rizzo M; Kelley MC; Meszoely IM; Arteaga CL
J Clin Invest; 2014 Dec; 124(12):5490-502. PubMed ID: 25401474
[TBL] [Abstract][Full Text] [Related]
40. Carboplatin treatment of antiestrogen-resistant breast cancer cells.
Larsen MS; Yde CW; Christensen IJ; Lykkesfeldt AE
Int J Oncol; 2012 Nov; 41(5):1863-70. PubMed ID: 22961366
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
